Overview Dividends

(BCPC) Balchem - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0576652004

Choline, Encapsulated Nutrients, Sterilants, Propylene Oxide, Chelated Minerals

EPS (Earnings per Share)

EPS (Earnings per Share) of BCPC over the last years for every Quarter: "2020-09": 0.83, "2020-12": 0.83, "2021-03": 0.87, "2021-06": 0.93, "2021-09": 0.92, "2021-12": 0.85, "2022-03": 1.03, "2022-06": 1.07, "2022-09": 1, "2022-12": 0.94, "2023-03": 0.94, "2023-06": 1.06, "2023-09": 1.04, "2023-12": 0.95, "2024-03": 1.03, "2024-06": 1.09, "2024-09": 1.13, "2024-12": 1.13, "2025-03": 1.22, "2025-06": 1.27, "2025-09": 1.35,
EPS Growth (3y CAGR): 14.07%
EPS Trend (3y Corr): 92.5%
Last SUE: 4.00σ
Qual. Beats: 2

Revenue

Revenue of BCPC over the last years for every Quarter: 2020-09: 175.14, 2020-12: 180.713, 2021-03: 185.656, 2021-06: 202.365, 2021-09: 197.869, 2021-12: 213.133, 2022-03: 228.867, 2022-06: 236.693, 2022-09: 244.267, 2022-12: 232.531, 2023-03: 232.54, 2023-06: 231.252, 2023-09: 229.948, 2023-12: 228.699, 2024-03: 239.659, 2024-06: 234.081, 2024-09: 239.94, 2024-12: 240.004, 2025-03: 250.519, 2025-06: 255.467, 2025-09: 267.558,
Revenue Growth (3y CAGR): 5.23%
Revenue Trend (3y Corr): 85.6%
Last SUE: 1.65σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 23.3%
Value at Risk 5%th 35.8%
Relative Tail Risk -6.62%
Reward TTM
Sharpe Ratio -0.69
Alpha -21.09
Character TTM
Hurst Exponent 0.662
Beta 0.558
Beta Downside 0.460
Drawdowns 3y
Max DD 23.10%
Mean DD 8.42%
Median DD 8.42%

Description: BCPC Balchem November 05, 2025

Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-organized into three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

In FY 2023 the company generated roughly $2.2 billion in revenue, with an operating margin of about 12 % and a 5 % year-over-year increase driven primarily by higher demand for its vitamin K2 and microencapsulation platforms in functional foods and dietary supplements. A key sector catalyst is the accelerating consumer shift toward fortified, “clean-label” products, which is expanding the addressable market for Balchem’s spray-dried powders and lipid delivery systems. On the animal side, tighter regulations on antibiotic use are boosting adoption of chelated minerals and choline-based feed additives, supporting the segment’s double-digit growth trajectory.

For a deeper, data-rich assessment of Balchem’s valuation dynamics, you may find it worthwhile to explore the company’s profile on ValueRay, where additional quantitative metrics and scenario analyses are available.

BCPC Stock Overview

Market Cap in USD 4,997m
Sub-Industry Specialty Chemicals
IPO / Inception 1986-06-03
Return 12m vs S&P 500 -22.9%
Analyst Rating 4.0 of 5

BCPC Dividends

Metric Value
Dividend Yield 0.56%
Yield on Cost 5y 0.87%
Yield CAGR 5y 10.67%
Payout Consistency 96.3%
Payout Ratio 17.5%

BCPC Growth Ratios

Metric Value
CAGR 3y 4.55%
CAGR/Max DD Calmar Ratio 0.20
CAGR/Mean DD Pain Ratio 0.54
Current Volume 287.6k
Average Volume 155.6k

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%)
Net Debt (90.7m) to EBITDA (260.1m) ratio: 0.35 <= 3.0 (WARN <= 3.5)
Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES)
Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 18.82 (EBITDA TTM 260.1m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3)

Altman Z'' 7.23

(A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b
(B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b
(C) 0.13 = EBIT TTM 204.3m / Avg Total Assets 1.63b
(D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m
Total Rating: 7.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.71

1. Piotroski 8.0pt
2. FCF Yield 3.18%
3. FCF Margin 15.94%
4. Debt/Equity 0.12
5. Debt/Ebitda 0.35
6. ROIC - WACC (= 3.34)%
7. RoE 12.12%
8. Rev. Trend 85.64%
9. EPS Trend 92.54%

What is the price of BCPC shares?

As of November 22, 2025, the stock is trading at USD 155.46 with a total of 287,606 shares traded.
Over the past week, the price has changed by -0.82%, over one month by -0.91%, over three months by -4.00% and over the past year by -13.33%.

Is BCPC a buy, sell or hold?

Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.
  • Strong Buy: 0
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the BCPC price?

Issuer Target Up/Down from current
Wallstreet Target Price 200.7 29.1%
Analysts Target Price 200.7 29.1%
ValueRay Target Price 157.4 1.3%

BCPC Fundamental Data Overview November 20, 2025

Market Cap USD = 5.00b (5.00b USD * 1.0 USD.USD)
P/E Trailing = 33.6893
P/E Forward = 30.1205
P/S = 4.93
P/B = 3.881
P/EG = 4.8341
Beta = 0.994
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.09b USD (5.00b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
FCF Yield = 3.18% (FCF TTM 161.6m / Enterprise Value 5.09b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.06 (Enterprise Value 5.09b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 260.1m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.86% (E(5.00b)/V(5.15b) * Re(8.07%) + D(155.8m)/V(5.15b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 80.71% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 153.7 (DCF Value 4.98b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: 92.54 | EPS CAGR: 14.07% | SUE: 4.0 | # QB: 2
Revenue Correlation: 85.64 | Revenue CAGR: 5.23% | SUE: 1.65 | # QB: 1

Additional Sources for BCPC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle